Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !

Dr Boreham's Crucible: Resapp Health

Biotech Daily Editorial: Welcome To 2017 

2016 - The Year In Review: Money, Malcolm & Medical Marijuana

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Novartis Buys Spinifex For $916m

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization


Summer BDI-40 Down 12%, ASX200 Up 3%
Big Caps Up 12%, NBI Up 2%


Mesoblast Up 40%, Living Cell 37%; Sirtex Down 48%, Impedimed 39%


February 1, 2017
The Biotech Daily Top 40 Index (BDI-40) fell 12.3 percent in the two months of the Australian Summer Holiday period.
Biotech Daily was unable to compile data for December 31, 2016, so today’s figures cover November 30, 2016 to January 31, 2017, as well as the year to January 31, 2017.
The ASX200 was up 3.3 percent for the two month period, while the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed a collective 12.3 percent, with the Nasdaq Biotechnology Index up 1.6 percent.
For the year to January 31, 2017, the BDI-40 fell 1.1 percent, the ASX200 was up 12.3 percent, the Big Caps rose 9.7 percent and the NBI was up 4.1 percent.
Nearly all of the BDI-40’s $970 million tumble was due to Sirtex losing $764 million or 47.9 percent to $830 million and Impedimed’s $176 million (38.5%) retreat to $281 million.
Interestingly, 19 of the BDI-40 companies were up, with 11 up by more than 10 percent, while 18 fell, with 10 down by more than 10 percent.
Following Sirtex and Impedimed down were: Factor Therapeutics (20.7%), Anteo (17.0%), Avita (15.1%), Nanosonics (14.3%), Airxpanders (13.4%) and Ellex (13.3%). Nanosonics has overtaken Sirtex as Australia’s largest market cap biotech after the Big Caps.
Mesoblast was the best, up 40.0 percent to $647 million, followed by Living Cell (37.0%), Uscom (21.7%), Opthea (20.5%), Medical Developments (17.8%) and Benitec (17.6%).
Outside the BDI-40, the President Trump-related Innate Immunotherapeutics has been on an upward roller coaster, climbing 62.7 percent for the two months to January 31, but up 708.8 percent for the year, while waiting for multiple sclerosis trial results. Medlab Clinical jumped 387.5 percent for the year, with Medibio up 194.7 percent, Cogstate up 139.7 percent and Phylogica up 133.3 percent.
On the Nasdaq, Aviragen (Biota) fell a further 9.6 percent to $66 million, while Israel’s Redhill was up 13.3 percent to $213 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to Jan 31, 2017 
BDI-40 v S&P ASX200 Jan 31, 2016 to Jan 31, 2017 
Big Caps (Cochlear, CSL, Resmed) Jan 31, 2016 to Jan 31, 2017


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At January 31, 2017



* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: